EP
MRNA icon

Eversept Partners’s Moderna MRNA Stock Holding History

Eversept Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
152,122
-7,586
-5% -$392K 0.55% 46
2026
Q1 		$8.11M Sell
159,708
-108,115
-40% -$5.04M 0.43% 48
2025
Q4 		$7.9M Buy
+267,823
New +$7.28M 0.4% 61

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Eversept Partners's MRNA Position: Q2 2026 in Review

Eversept Partners reduced its Moderna (MRNA) stake by 4.7% in Q2 2026, selling an estimated $392K and leaving 152,122 shares worth $10.7M. The position accounts for 0.55% of the portfolio, ranked #46.

Eversept Partners first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Eversept Partners held 152,122 shares of Moderna worth $10.7M as of Q2 2026.
  • Eversept Partners sold 7,586 Moderna shares in Q2 2026, an estimated $392K.
  • Moderna made up 0.55% of Eversept Partners's portfolio in Q2 2026, its #46 holding.
  • Eversept Partners first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.